Overview

Preoperative Chemoradiotherapy With Cetuximab in Rectal Cancer

Status:
Unknown status
Trial end date:
2010-05-01
Target enrollment:
Participant gender:
Summary
This study is to estimate the pathologic complete response rate of cetuximab, irinotecan, and capecitabine concurrent with radiotherapy given preoperatively in patients with resectable rectal cancer.
Phase:
Phase 2
Details
Lead Sponsor:
National Cancer Center, Korea
Treatments:
Capecitabine
Cetuximab
Irinotecan